Market Cap
$9.0B
CRNX
Crinetics Pharmaceuticals, Inc.
—
Market cap$9.0B
ConsensusSell
12-mo target$85.00 (+0.1%)
▼ Bearish
Analyst conviction 3/10
Insider Selling Cluster (2 insiders)High Impact Filing (9/10)17 New Institutional Positions9 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on CRNX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Hold (30%)
Inst. Holders
50 funds
Inst. Value
$3.6B
Inst. Activity
17 buys / 9 sells
SEC Reports
13
Press Releases
2
Congressional
1 trades
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 11, 2026 SEC Sep 1, 2026 SEC
Crinetics Pharmaceuticals filed Form 15-12G to terminate its SEC registration under Section 12(g), effective September 1
15-12G — Impact 9/10
Sep 2, 2026 listing_status
Sep 1, 2026 SEC Delisted: CRNX — removed from the Nasdaq symbol directory
Crinetics Pharmaceuticals, Inc. - Common Stock
Nasdaq has filed Form 25 to delist Crinetics Pharmaceuticals (CRNX) common stock effective September 1, 2026, following
25-NSE — Impact 9/10
Crinetics Pharmaceuticals has been acquired by Vertex Pharmaceuticals in an all-cash merger that closed on September 1,
8-K — Impact 9/10
Sep 1, 2026 Insider
Bedrosian Camille L disposed of 16,300 shares
Director @ $85.00 ($1.4M)
Sep 1, 2026 Insider
Bedrosian Camille L disposed of 5,925 shares
Director @ $85.00 ($503.6K)
Sep 1, 2026 Insider
Bedrosian Camille L disposed of 17,500 shares
Director @ $66.71 ($1.2M)
Aug 14, 2026 Event
HSR Early Termination: Vertex Pharmaceuticals Incorporated; Crinetics Pharmaceuticals, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Vertex P
Analyst ratings buy % -65.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
30% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 28, 2026 | UBS | DOWNGRADE | Neutral | 55% |
| Jul 8, 2026 | TD Cowen | DOWNGRADE | Hold | 56% |
| Jul 8, 2026 | Evercore ISI Group | DOWNGRADE | In-Line | 59% |
| Jul 7, 2026 | Jones Trading | DOWNGRADE | Hold | 51% |
| Jul 7, 2026 | Jefferies | DOWNGRADE | Hold | 53% |
| Jul 7, 2026 | Oppenheimer | DOWNGRADE | Perform | 52% |
| Jul 7, 2026 | Cantor Fitzgerald | DOWNGRADE | Neutral | 49% |
| Jul 7, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Jul 7, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Jul 2, 2026 | UBS | INITIATE | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 3 | 14 | 0 | 0 | 30% | |
| Aug 1, 2026 | 3 | 4 | 14 | 0 | 0 | 33% | |
| Jul 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Feb 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% |
Price targets
Where 8 covering analysts think CRNX trades over the next 12 months.
$85.00 +0.1% upside Hold
Current$84.95 Low$85.00 Median$85.00 High$85.00 8 analysts
$85.00$85.00
Analyst rating Hold· 2.8/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
13 SEC filing reports analyzed · 7 bullish, 1 bearish, 1 mixed, 4 neutral · avg impact 6.2/10.Plus 2 press releases.
BULLISH15-12G9/10
Crinetics Pharmaceuticals filed Form 15-12G to terminate its SEC registration under Section 12(g), e
Sep 11, 2026
BULLISH25-NSE9/10
Nasdaq has filed Form 25 to delist Crinetics Pharmaceuticals (CRNX) common stock effective September
Sep 1, 2026
BULLISH8-K9/10
Crinetics Pharmaceuticals has been acquired by Vertex Pharmaceuticals in an all-cash merger that clo
Sep 1, 2026
BULLISH8-K6/10
Vertex's acquisition of Crinetics cleared all major antitrust hurdles: HSR waiting period expired Au
Aug 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 10, 2026
Clinical Trial
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Phase Phase 2 — COMPLETED
Sep 2, 2026
listing_status
Delisted: CRNX — removed from the Nasdaq symbol directory
Crinetics Pharmaceuticals, Inc. - Common Stock
Sep 2, 2026
trading_halt
Halt Resumed: CRNX — trading resumed after D (Security Deletion)
Halted 2026-08-31T23:50:00.000Z | Resumed 2026-09-02T04:00:01.000Z
Sep 1, 2026
ftd
FTD: CRNX — 518,283 shares ($44.0M) failed to deliver
Settlement: 20260901, Price: $84.95, FTD Value: $44,028,140.85, CRINETICS PHARMACEUTICALS INC
Aug 31, 2026
trading_halt
Trading Halt: CRNX — T12 (Additional Information Requested)
Crinetics Pharmaceutical Cm St | Market: NASDAQ | Code: T12 — Additional Information Requested
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.13 | $-1.26–$-0.88 | 17.8% | +3.6% | 1↑ 0↓ | $0.0B | 8 |
| Next Q | $-1.07 | $-1.25–$-0.80 | 17.0% | +6.7% | 1↑ 0↓ | $0.1B | 8 |
| Current FY | $-4.54 | $-4.99–$-3.48 | 8.3% | +1.8% | 1↑ 0↓ | $0.2B | 8 |
| Next FY | $-4.01 | $-5.12–$-2.48 | 11.6% | +1.4% | 2↑ 0↓ | $0.2B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.134 | — |
| 7d ago | $-1.124 | -0.009 |
| 30d ago | $-1.177 | +0.043 |
| 60d ago | $-1.221 | +0.087 |
| 90d ago | $-1.221 | +0.087 |
Institutional ownership
Which big funds own CRNX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.6B total value (96,733,552 shares) as of 2026-Q2. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 17 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 15,840,219 | $592.7M | 16.4% | — |
| BlackRock, Inc. | 9,758,938 | $365.2M | 10.1% | — |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 8,989,098 | $336.4M | 9.3% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 7,131,084 | $266.8M | 7.4% | — |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 6,463,551 | $241.9M | 6.7% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,832,614 | $180.8M | 5.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,745,262 | $177.6M | 4.9% | — |
| Jupiter Topco LLC | 4,557,689 | $170.5M | 4.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,727,633 | $102.1M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Polar Capital Holdings Plc | NEW | — | 2,274,411 | — | $85.1M |
| MORGAN STANLEY | ADD | 919,686 | 1,338,531 | +45.5% | $50.1M |
| BANK OF AMERICA CORP /DE/ | ADD | 716,125 | 1,333,071 | +86.2% | $49.9M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 852,258 | 1,270,531 | +49.1% | $47.5M |
| MARSHALL WACE, LLP | ADD | 684,108 | 1,126,639 | +64.7% | $42.2M |
| GOLDMAN SACHS GROUP INC | ADD | 628,155 | 1,104,998 | +75.9% | $41.3M |
| AMERIPRISE FINANCIAL INC | TRIM | 798,334 | 497,205 | -37.7% | $18.6M |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 382,363 | 480,504 | +25.7% | $17.7M |
| Fiera Capital Corp | TRIM | 589,654 | 338,841 | -42.5% | $12.7M |
| JENNISON ASSOCIATES LLC | NEAR_EXIT | 904,672 | 161,861 | -82.1% | $6.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Bedrosian Camille L | Director | D | 16,300 | $85.00 | $1.4M |
| Sep 1, 2026 | Bedrosian Camille L | Director | D | 5,925 | $85.00 | $503.6K |
| Sep 1, 2026 | Bedrosian Camille L | Director | D | 17,500 | $66.71 | $1.2M |
| Sep 1, 2026 | Bedrosian Camille L | Director | D | 25,000 | $68.92 | $1.7M |
| Sep 1, 2026 | Bedrosian Camille L | Director | D | 10,350 | $52.67 | $545.1K |
| Sep 1, 2026 | Fust Matthew K | Director | D | 2,092 | $83.09 | $173.8K |
| Sep 1, 2026 | Bedrosian Camille L | Director | D | 17,500 | $64.77 | $1.1M |
| Sep 1, 2026 | Kalofonos Isabel | Chief Commercial Officer | D | 1,669 | $85.00 | $141.9K |
| Sep 1, 2026 | Bedrosian Camille L | Director | D | 17,500 | $64.68 | $1.1M |
| Sep 1, 2026 | Bedrosian Camille L | Director | D | 12,500 | $40.29 | $503.6K |
Congressional trades
CRNX trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Gilbert Cisneros | D | HOUSE | SELL | $15,001 - $50,000 | CRINETICS PHARMCTCL INC | Sep 7, 2026(40d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CRNX.
Shares short
6,847,147
Settlement Aug 31, 2026
Change vs prior
+3.9%
Semi-monthly cycle
Days to cover
2.4
At avg daily volume
Of shares outstanding
≈6.5%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Aug 31, 2026 | T12 | Info Requested | Not resumed |
| Aug 31, 2026 | D | Deletion | Resumed |
All CRNX filing & press-release reports (15)
- 15-12G reportSep 11, 2026
- 25-NSE reportSep 1, 2026
- 8-K reportSep 1, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 3, 2026
- 8-K reportJul 10, 2026
- DEFA14A reportJul 10, 2026
- PRESS-RELEASE reportJun 30, 2026
- PRESS-RELEASE reportJun 14, 2026
- PRESS-RELEASE reportJun 14, 2026
- 8-K reportMay 7, 2026
- 8-K reportApr 10, 2026
- PRESS-RELEASE reportApr 8, 2026
- CLUSTER reportMar 18, 2026
- 8-K reportFeb 26, 2026